0241.HK

Online medical services provider Alibaba Health Information Technology Ltd. (0241.HK) said Wednesday its revenue rose 10.2% year-on-year to 14.27 billion yuan ($1.98 billion) in the six months through September. It credited the growth to a 67.5% jump in revenue from its pharmaceutical e-commerce platform business, which was partly offset by a 9.4% drop in revenue from its healthcare and digital services business.

The company’s net profit during the period, the first half of its fiscal year, surged by 72.5% to 770 million yuan. It attributed the strong gains to the revenue increase, as well as improving operational efficiencies for its self-operated pharmaceutical business, including its introduction of more top brands and expansion of its partnership channels.

The company’s stock rose 3.3% to HK$4.27 in early Thursday trade in Hong Kong.

By A. Au

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

vitasoy

Singapore business dynasty has Vitasoy in its sights

The Hong Kong beverage brand has been recovering from a sales slump in mainland China, but its founding family could now face a takeover challenge Key Takeaways: Vitasoy’s profits rose…
Xuanzhu Biopharm set for spin-off in Hong Kong IPO

Xuanzhu Biopharm set for spin-off in Hong Kong IPO

The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu…